Background: Galectin-3, a biomarker associated with cardiac remodeling, has been linked to poor outcomes in patients with acute STEMI. Understanding its predictive capacity after primary percutaneous coronary intervention [PPCI] is critical for improving patient management.
The aim of the work: This study investigates the correlation between admission levels of Galectin-3 and the occurrence of cardiac remodeling in patients diagnosed with acute STEMI following PPCI.  
Patients and Methods: A total of 90 consecutive patients presenting with chest pain and diagnosed with acute STEMI were included. Patients were divided into two groups based on remodeling status—Group I [non-remodelers, n=58] and Group II [remodelers, n=32]—defined by an increase in left ventricular end-diastolic volume [LVEDV] of more than 20% from baseline echocardiography. Cardiovascular metrics, including LVEDV, left ventricular end-systolic volume [LVESV], ejection fraction [EF%], and serum levels of Galectin-3, troponin, and CKMB were assessed at baseline and after three months.
Results: Significant differences were observed between groups in LVEDV, LVESV, and EF% after three months [p=0.001]. Galectin-3 levels were significantly higher in remodelers [mean 16.59] compared to non-remodelers [mean 12.62, p<0.001]. Troponin and CKMB levels also differed significantly between groups [p<0.001]. TIMI flow showed significant differences at both baseline and post-PPCI [p=0.014 and p= 0.003, respectively]. Pearson's correlation coefficient between Galectin-3 levels and cardiac remodeling was 0.84, indicating a strong positive relationship, with an AUC of 0.997 for predictive capacity.
Conclusion: Admission levels of Galectin-3 are strongly correlated with cardiac remodeling post-PPCI in STEMI patients. This biomarker could serve as a valuable predictor for assessing risk and managing treatment strategies in this population.